Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs): As part of routine treatment.
Study summary
The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.
Eligibility
Sex
ALL
Min age
65 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be enrolled in the study:
1. Age ≥65 years old;
2. Diagnosed with cancer;
3. Using antineoplastic drugs for treatment.
Exclusion Criteria:
Subjects with any of the following criteria will not be enrolled in this study:
1. Patients who are expected to die within 48 hours;
2. Patients with allergy to antineoplastic drugs;
3. Patients receiving other investigational drugs;
4. Other factors that the researcher considers unsuitable for inclusion.
Primary outcome measure(s)
The peak plasma drug concentration of antineoplastic drugs. — at (0-4) hours after administration To detect the peak plasma drug concentration of antineoplastic drugs.
The random plasma drug concentration of antineoplastic drugs. — at (4-10) hours after administration To detect the random plasma drug concentration of antineoplastic drugs.
The trough plasma drug concentration of antineoplastic drugs. — at (1-2) hours before the next administration To detect the trough plasma drug concentration of antineoplastic drugs.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.